Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 18;10:22346. doi: 10.1038/s41598-020-79170-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Study Design: Remitted patients on antidepressant medication (ADM) and matched healthy controls were included in the study and assessed during main assessment 1 (MA1). Patients were randomised to groups MA1-D-MA2 or MA1-MA2-D, where the name indicates the order of events and "D" indicates discontinuation. In group MA1-D-MA2, they underwent MA1, then discontinued their medication followed by main assessment 2 (MA2). In group MA1-MA2-D, they underwent MA1 and MA2 first and only discontinued thereafter. After discontinuation, all patients were followed up for six months to ascertain relapses. Comparison of patient and control groups at MA1 was used to examine the remitted medicated state cross-sectionally (orange). Data collected at MA1 from all patients who subsequently completed the study as relapsers or non-relapsers, i.e. relapsers and non-relapsers from both groups combined were examined to examine associations with relapse. The interaction between time point (MA1 and MA2) with group (MA1-D-MA2 and MA1-MA2-D) examined the impact of discontinuation (blue). Finally, the interaction between time point (MA1 and MA2) and relapse in group MA1-D-MA2 was used to examine changes due to discontinuation that led to relapse or resilience (dark green).